Pregnant patients with antiphospholipid syndrome (APS) may suffer from recurrent pregnancy loss, pre-eclampsia, intrauterine growth restriction and placental abruption. These conditions inevitably result in a high incidence of premature delivery with all the neonatal complications that follow. The mechanism underlying these adverse pregnancy outcomes has not yet been established. This may be primarily a maternal disease process with secondary placental maldevelopment and/or malfunction. Alternatively, there may be primary placental damage mediated directly or indirectly by antiphospholipid antibodies. The safe and successful treatment of pregnant women with APS lies in the understanding of the aetiology of this condition and the mechanism by which complications in pregnancy may arise. In this article we highlight areas in which research may be targeted such that our understanding of the pathogenesis of adverse pregnancy outcome may be enhanced.
Maclean M., Cumming G., McCall F., Walker I., Walker J.The prevalence of lupus anticoagulant and anticardiolipin antibodies in women with a history of first trimester miscarriages. Br J Obstet Gynaecol1994; 101: 103-106.
Rai RS, Clifford K., Cohen H., Regan L.High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod1995; 10: 3301-3304.
4.
Lockwood CJ et al. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin in a general obstetric population. Am J Obstet Gynaecol1989; 161: 369—373.
5.
Perez MC, Wilson WA, Brown HL, Scopelitis E.Anti-cardiolipin antibodies in unselected pregnant women in relationship to fetal outcome. J Perinatol1991; 11: 33-36.
6.
Branch DW, Scott JR, Kochenour NKObstetric complications associated with lupus anticoagulant. N Engl J Med1985; 313: 1322-1326.
Branch DW et al. The association of antiphospholipid antibodies with severe pre-eclampsia . Obstet Gynecol1988; 73: 541-545.
9.
Moodley J. et al. The association of antiphospholipid antibodies with severe early-onset pre-eclampsia. South Afr Med J1995; 85: 105-107.
10.
Dekker GA et al. Underlying disorders associated with severe early-onset pre-eclampsia . Am J Obstet Gynaecol1995; 173: 1042—1048.
11.
Birdsall MA , Pattison NS, Chamley L.Antiphospholipid antibodies in pregnancy. Austr N Z J Obstet Gynaecol1992; 32: 328—330.
12.
Balasch J. et al. Low-dose aspirin for prevention of pregnancy losses in women with antiphospholipid syndrome. Hum Reprod1993; 8: 2234-2239.
13.
Kutteh WHAntiphospholipid antibody-associated recurrent pregnancy loss—treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynaecol1996; 174: 1584-1589.
14.
Rai R., Cohen H., Dave M., Regan L.Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J1997 ; 314: 253-257.
15.
Rivier G. et al. Thrombosis and antiphospholipid syndrome: a preliminary assessment of three antithrombotic treatments. Lupus1994; 3: 85—90.
16.
Hunt BJ, Khamashta MA, Lakasing L., Williams F., Hughes Grv.Thromboprophylaxis in antiphospholipid syndrome pregnancies with previous cerebral arterial thrombotic events: is warfarin preferable?Thromb Haemost1997 (in press).
17.
Lockshin MD , Druzin ML, Qamar T.Prednisolone does not prevent recurrent fetal death in women with antiphospholipid antibody. Am J Obstet Gynaecol1989; 160: 439—443.
18.
Cowchock FS , Reece EA, Balaban D., Branch DW, Plouffe L.Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomised trial comparing prednisolone with low-dose heparin treatment. Am J Obstet Gynaecol1992 ; 166: 1318-1323.
19.
Spinnato JA , Clark AL, Pierangeli SS, Harris ENIntravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy. Am J Obstet Gynaecol1995; 172: 690-694.
20.
Lima F. et al. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumat1996; 14: 131-136.
21.
Branch DW et al. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah Experience. Obst Gynaecol1992; 80: 614-620.
22.
Cowchock S. , Reece EADo low-risk pregnant women with antiphospholipid antibodies need to be treated? Am J Obstet Gynecol1997; 176: 1099—1100.
23.
CLASP (Collaborative low-dose aspirin study in pregnancy) Collaborative Group.CLASP: a randomised trial of low-dose aspirin for the prevention and treatment pre-eclampsia among 9364 pregnant women. Lancet1994; 343: 619—629.
24.
Botet F., Romera G., Montagut P., Carmona F., Balasch J.Neonatal outcome in women treated for the antiphospholipid syndrome during pregnancy. J Perinat Med1997; 25: 192—196.
25.
Dahlman TCOsteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin . Am J Obstet Gynecol1993; 168: 1265-1270.
26.
Nelson-Piercy C.Heparin-induced osteoporosis in pregnancy . Lupus1997; 6: 500-504.
27.
De Wolf F. et al. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant. Am J Obstet Gynaecol1982; 142: 829—834.
28.
Erlendsson K. , Steinsson K., Johannsson JH, Geirsson RTRelation of antiphospholipid antibody and placental bed inflammatory vascular changes to the outcome of pregnancy in successive pregnancies of 2 women with systemic lupus erythematosus. J Rheumatol1993; 20: 17791785.
29.
Hanly JG et al. Lupus pregnancy. A prospective study of placental changes. Arthritis Rheum1988; 31: 358—366.
30.
Peaceman AM , Rehnberg KAThe effect of immunoglobulin G fractions from patients with lupus anticoagulant on placental prostacyclin and thromboxane production. Am J Obst Gynaecol1993; 169: 1403-1406.
31.
Lala PK, Hamilton GSGrowth factors, proteases and protease inhibitors in the maternal-fetal dialogue . Placenta1996; 17: 545-555.
32.
McMaster MT , Bass KE, Fisher SJHuman trophoblast invasion, Autocrine control and paracrine modulation. Ann New York Acad Sci1994; 734: 122—131.
33.
Guilbert L. , Robertson SA, Wegmann TGThe trophoblast as an integral component of a macrophage-cytokine network. Immunol Cell Biol1993; 71: 49-57.
34.
Burrows TD, King A., Loke YWTrophoblast migration during human placental implantation. Hum Reprod Update1996; 2: 307—321.
Aplin JDThe cell biology of human implantation. Placenta1996; 17: 269-275.
38.
McMaster MT et al. Human placental HLA-G expression is restricted to differentiated cytotrophoblasts. J Immunol1995; 154: 3771—3778.
39.
Katano K. et al. Specific antiphospholipid antibodies (aPL) eluted from placentae of pregnant women with aPL-positive sera. Lupus1995; 4: 304-308.
40.
Arbogast BW et al. Which plasma factors bring about disturbance of endothelial function in pre-eclampsia?Lancet1994; 343: 340-341.
41.
Morris NH, Eaton BM, Dekker G.Nitric oxide, the endothelium, pregnancy and pre-eclampsia. Br J Obstet Gynaecol1996; 103: 4-15.
42.
Poston L.Maternal vascular function in pregnancy. J Hum Hypertens1996;10: 391-394.
43.
Del Papa N. et al. Endothelial cells as target for antiphospholipid antibodies human polyclonal and monoclonal anti B2-glycoprotein I antibodies react in vitro with endothelial cells through adherent B 2glycoprotein I and induce endothelial activation. Arthritis Rheum1997; 40: 551-561.
44.
Labarrere CA , Faulk WPIntercellular adhesion molecule-1 (ICAM-1) and HLA-DR antigens are expressed on endovascular cytotrophoblasts in abnormal pregnancies. Am J Reprod Immunol1995; 33: 47—53.
45.
Lyall F. et al. Expression of cell adhesion molecules in placentae from pregnancies complicated by pre-eclampsia and intrauterine growth retardation. Placenta1995; 16: 579-587.
46.
Roubey Ras.Autoantiboides to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other 'Antiphospholipid' autoantibodies. Blood1994; 84: 2854—2867.
47.
Galli M. et al. Anticardiolipin antibodies directed not to cardiolipin but to a plasma protein cofactor. Lancet1990; 335: 1544.
48.
Fleck RA, Rapaport SI, Viiaya Mohan Rao L.Anti-prothrombin antibodies and the lupus anticoagulant. Blood1988; 72: 512—519.
49.
Ogasawara M. et al. Anticardiolipin antibodies in patients with pregnancy loss induce factor Xa production in the presence of beta-2-glycoprotein 1. Am J Reprod Immunol1995; 34: 269—273.
50.
Katano K. et al. Beta-2 glycoprotein I dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. Hum Reprod1996; 11: 509—512.
51.
Labarrere CA , Faulk WPFetal stem vessel endothelial changes in placentae from normal and abnormal pregnancies. Am J Reprod Immunol1992; 27: 97-100.
52.
Labarrere CA , Faulk WPMicrovascular perturbations in human allografts: analogies in pre-eclamptic placentae. Am J Reprod Immunol1992; 27: 109—116.
53.
Cuadrado MJ et al. Thrombosis in primary antiphospholipid syndrome. A pivotal role for monocyte tissue factor expression. Arthritis Rheum1997; 40: 834-841.
54.
Krikun G. et al. The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: immunolocalisation and in vitro regulation. Placenta1994; 15: 601-612.
55.
Rand JH et al. Reduction of annexin V (placental anticoagulant protein-1 ) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am J Obstet Gynaecol1994; 171: 1566-1572.
56.
Rand JH et al. Pregnancy loss in the antiphospholipid-antibody syndrome—a possible thrombogenic mechanism. N Engl J Med1997; 337: 154-160.
